Vonvendi Disease Interactions
There is 1 disease interaction with Vonvendi (von willebrand factor).
Von Willebrand factor (applies to Vonvendi) thromboembolic reactions
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Thrombotic/Thromboembolic Disorder, History - Thrombotic/Thromboembolic Disorder
Thromboembolic reactions including disseminated intravascular coagulation (DIC), venous thrombosis, pulmonary embolism, myocardial infarction, and stroke can occur after therapy with von Willebrand factor, particularly in patients with risk factors for thrombosis. Monitor for early signs and symptoms of thrombosis such as pain, swelling, discoloration, dyspnea, cough, hemoptysis, and syncope and have prophylaxis measures against thromboembolism instituted according to current recommendations.
References
- (2022) "Product Information. Humate-P (antihemophilic factor-von Willebrand factor)." CSL Behring LLC
- (2022) "Product Information. Wilate (antihemophilic factor-von Willebrand factor)." Octapharma USA
Vonvendi drug interactions
There is 1 drug interaction with Vonvendi (von willebrand factor).
More about Vonvendi (von willebrand factor)
- Vonvendi consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- FDA approval history
- Drug class: miscellaneous coagulation modifiers
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.